

ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

BIO-GENE TECHNOLOGY LIMITED

3 MAY 2023

Company Update

PRESENTED BY

Richard Jagger

CEO

Peter May

Exec Director, R&D



BIO-GENE
TECHNOLOGY
LTD



DISCLAIMER

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. No representation, warranty or guarantee, express or implied, is given that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

Any statement made in or during the course of this presentation relating to efficacy, market segments, fields of use, products, applications or synergy is to be taken in context of the disclosures made in published patent applications owned by the Company, a list of which may be provided upon request, and the disclosure of each of which is hereby incorporated by reference in its entirety.

BUSINESS UPDATE AGENDA

- Global challenges & pest control
- Bio-Gene's chemistry & technology platform
- Target Market defined
- Commercialisation pathway & Business Model
- Revenue expectations
- Key partnerships in target segments
- Synergy studies & the upside
- Summary
- Next Steps

GLOBAL CHALLENGES AND RESISTANT PEST CONTROL

Food Security & Public Health

- Growing Population = more food
- Climate Change = more mosquitos

Financial Impact

- Production lost to pests = higher costs, lost income
- Direct & economic impact of disease

Social Impact

- Vector Borne Disease = increased risk to more humans
- More people = Less Arable Land



“Without Crop Protection, crop losses would double each year”

CropLife




“No new public health insecticides have been developed for mainstream vector control for 30 years”

CDC

BIO-GENE'S CHEMISTRY IS A STEP-CHANGE FOR RESISTANT PEST CONTROL

- **Novel Mode of Action (MoA)**
 - Last new MoA commercialised in 2008, with current sales of US\$2.3bn
- **Naturally derived and safe chemistry**
- **Efficacy across a number of target pests**
- **Addresses multiple market segments**
 - Crop protection, grain storage, consumer applications, public health & animal health
- **Third Party Validation**
 - Multiple commercial deals with industry leading companies
- **Multiple revenue streams**
 - Licensing fees, milestone payments, active ingredient supply, royalties



Qcide™

Natural Compound

An extract of a specific cultivar of eucalypt, the Gypmie Messmate

Trees farmed in QLD

The leaves contain oil expressing high levels of Tasmanone,



Flavocide™


Nature Identical Compound

Active ingredient Flavesone is found in Nature

Synthesised via new proprietary process

Can be produced in large volumes globally

TARGET MARKETS



Bio-Gene's products target five key market segments

COMMERCIALISATION PATHWAY AND BUSINESS MODEL

Commercialisation pathway


- Active ingredient registrations
- Product development, Marketing & distribution with strong commercial partners
- Developing proprietary manufacturing and production know-how

Revenue drivers

1. Technology licensing fees
2. Milestone payments
3. Active ingredient supply
4. Royalties

REVENUE EXPECTATIONS

Revenue profile (\$m)



Bio-Genex expects highly profitable revenue streams from FY 2026 onwards

TARGET MARKET: PUBLIC HEALTH CLARKE COMMERCIAL DEVELOPMENT AGREEMENT

Clarke is the largest vertically integrated company in public health mosquito control

Extended Commercial Agreement

Now includes professional residential applications

Adds an additional US\$150m market opportunity

Milestones and future royalty payments aligned with original agreement

Territory: USA & Cayman Islands

Validation of work to date

Excellent collaboration between the two companies

Cost of studies borne by Clarke, with shared report of results

Revenue Model

Up-front licence fee

Milestone payments prior to registration

On-going royalties on end-use product sales

Development costs borne by Clarke

Next Steps

Targeted formulation development for different applications

Field studies designed to confirm suitability for field use & EPA registration



Market Opportunity

Initial Field of Use:
US\$100m¹

Extended Field of Use:
US\$250m

TARGET MARKET: CONSUMER PRODUCTS EVERGREEN COMMERCIAL DEVELOPMENT AGREEMENT

Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand

Initial Field of Use

Flying insect control

Crawling insect control

ROFR to negotiate additional applications within consumer market

Initial Territory

E.U., U.K., ANZ

ROFR to negotiate additional territories within consumer market

Other market opportunities

Actively exploring additional market opportunities to add to our agreement

Revenue Model

Up-front licence fee

Milestone payments prior to registration

On-going royalties on end-use product sales

Development costs borne by Evergreen

Next Steps

Continue development of market opportunities

Collaborate on registration activities

Strong relationship is emerging between the two companies



Market Opportunity

Initial Field of Use:
US\$600m¹

Total European
consumer insecticide
market: US\$2b¹

TARGET MARKET: CROP PROTECTION BINDING TERMS AGREED WITH STK BIO-AG

STK applies advanced botanical science and bio-ag technology in the development & commercialisation of natural crop protection solutions for growers worldwide

Licencing arrangements

STK granted a global non-exclusive licence to develop Qcide for crop protection, aquaculture, & professional turf & ornamental markets

Opportunities to expand manufacturing capabilities

Work with STK to expand production globally drawing on multiple manufacturing sites for ingredient supply

Significant market opportunity

Crop Protection globally is a US\$16 B p.a. business¹. Opportunities for botanical/natural products within this market are increasing rapidly

Registering Active Ingredient

STK will fully fund the registration of Qcide A.I.

Bio-Gene has full registration access to work with partners exclusively in public health, consumer, animal health, & non-exclusively in crop protection, aquaculture & professional turf & ornamental markets

Bio-Gene retains IP relating to Qcide

Revenue Model

Active ingredient supply to STK

On-going royalties on end use product sales with other commercial partners

Alliance, partnerships

Bio-Gene working with STK to develop opportunities for the Qcide business as botanical biopesticides

Evaluation of opportunity for Bio-Gene to be ANZ agent for STK products

Next Steps

Finalise transaction documentation

Develop advisory committee to drive registration of A.I. & develop manufacturing capabilities

Explore agency opportunities



Market Opportunity

Sales of Active Ingredient to STK

Utilisation of STK funded registration for our key markets

Royalty opportunities with BGT customers

¹ Fortune business insights, 2021: Crop protection chemicals market size... 2021-2028.

EXPLAINING SYNERGY – THE HOLY GRAIL

What is Synergy?

- Synergy occurs when the effect of two or more agents (or compounds) in combination is greater than the additive effect of those same agents

Why does Synergy occur?

- Synergy is unpredictable and uncommon, but it can occur when different Modes of Action of two insecticidal compounds interact in a way that enhances the mode of action of one or both compounds.

How is Synergy assessed?

- Using dose range finding tests to determine rates that cause mortality over the range 0% to 100%
- Combination testing of compounds at sub-lethal concentrations
- Statistical analysis of data


What was tested¹?

- Both Flavocide & Qcide tested in combination with particular commercially important compounds from the chemical groups of pyrethrins, pyrethroids, diamides, carbamates, organophosphates
- Against particular target insect pest species, including both susceptible & resistant strains



STUDIES CONFIRM SYNERGY

Synergy confirmed with Qcide/Pyrethrin combination¹



¹In spray/topical applications, Qcide with pyrethrins against houseflies (*M. domestica*).

- Novel Mode of Action allows for this synergistic effect
- Cost effective at lower rates

Statistically valid results confirmed synergy in this combination

COMMERCIAL OPPORTUNITIES VIA SYNERGY

- Significantly expands commercial opportunities in global insecticide market:
 - Lower dosage requirements, reduced cost and improved environmental safety
 - Addresses resistance issues
 - Extends the value of commercial partner post-patent products with added benefit of increased efficacy against resistant pests
- Synergy shown for particular important molecules & target pests creates opportunity for multiple commercial partnerships & applications
- Reinforces value of Bio-Gene products' unique Mode of Action to provide more effective control and address resistance of pests to these insecticides
- Results support Bio-Gene patents – valuable to commercial partners
- Early-stage results led to a new Material Transfer Agreement with a global company

Synergy creates multiple opportunities and significant value for Bio-Gene and its partners

MANUFACTURING DEVELOPMENTS

- As reported in December 2022 significant progress have been across:
 - Production know-how & trade secrets
 - Scalability of product
 - Cost management
 - Process improvements
 - Manufacturing partner engagement
 - Data development for registration dossiers

SUMMARY

- There is a real need for new Mode of Action insecticides globally
- Our chemistry has been validated by commercial parties
- Key initial partnerships have been established with many more planned
- Business model is developed
- Synergy study results expand commercial opportunities
- We will continue to focus on execution of the plan

NEXT STEPS

- Finalise STK agreement
- Additional Synergy testing
- Advance other commercial partnerships
- Deliver manufacturing partnerships
- Further strengthen our IP platform
- Advance our regulatory applications with governing bodies
- Continue to advance our business model via licences, milestones, active ingredient sales & royalties

ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

BIO-GENE TECHNOLOGY LIMITED

BIO-GENE
TECHNOLOGY
LTD

Q&A

richardj@bio-gene.com.au

peterm@bio-gene.com.au

rodv@bio-gene.com.au

www.bio-gene.com.au



SOURCES

Slide	Sources
6	US EPA 2017, WHO 2017, Zoetis & Provue Market Research, Markets & Markets
9	Global Mosquito Control Market, Research Report 2020, Forecast to 2026
10	Research and Markets report, December 2019: Europe Household Insecticides Market to 2027 - Regional Analysis and Forecasts By Insect Type; Composition; Packaging; Distribution Channel.
11	Fortune business insights, 2021: Crop protection chemicals market size... 2021-2028.
12	What was tested in synergy studies? - Flavocide in spray/topical applications: with pyrethrins against houseflies (<i>Musca domestica</i>); with pyrethroid Permethrin against houseflies (<i>M. domestica</i>) and mosquitoes (<i>Aedes aegypti</i>); with pyrethroid alpha-Cypermethrin against aphids (<i>Myzus persicae</i>); with diamide Chlorantraniliprole against resistant diamondback moth (<i>Plutella xylostella</i>); with carbamate Pirimicarb against aphids (<i>M. persicae</i>); with organophosphate Dimethoate against aphids (<i>M. persicae</i>). Qcide in spray/topical applications: with pyrethrins against houseflies (<i>M. domestica</i>); with pyrethroid Permethrin against houseflies (<i>M. domestica</i>) and mosquitoes (<i>A. aegypti</i>) including resistant strains.